TR201110524A2 - Kemik hastalıklarının tedavisinde kullanılmak üzere suda çözünebilir yeni formülasyonlar. - Google Patents

Kemik hastalıklarının tedavisinde kullanılmak üzere suda çözünebilir yeni formülasyonlar.

Info

Publication number
TR201110524A2
TR201110524A2 TR2011/10524A TR201110524A TR201110524A2 TR 201110524 A2 TR201110524 A2 TR 201110524A2 TR 2011/10524 A TR2011/10524 A TR 2011/10524A TR 201110524 A TR201110524 A TR 201110524A TR 201110524 A2 TR201110524 A2 TR 201110524A2
Authority
TR
Turkey
Prior art keywords
treatment
bone diseases
new water
soluble formulations
bone
Prior art date
Application number
TR2011/10524A
Other languages
English (en)
Inventor
Bi̇lgi̇ç Mahmut
Original Assignee
Bi̇lgi̇ç Mahmut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from TR2011/00151A external-priority patent/TR201100151A2/tr
Application filed by Bi̇lgi̇ç Mahmut filed Critical Bi̇lgi̇ç Mahmut
Priority to TR2011/10524A priority Critical patent/TR201110524A2/tr
Priority to PCT/TR2012/000006 priority patent/WO2012093975A1/en
Publication of TR201110524A2 publication Critical patent/TR201110524A2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Su oranı ağırlıkça % 11 'den az olan etken madde kullanılarak hazırlanan suda çözünebilir formülasyonlar ve bunların üretim yöntemleri ile ilgilidir. Buluş konusu formülasyonlar, hiperkalsemi, osteoporoz, tümör osteolizi, malin hiperkalsemi, metastatik kemik hastalığı, periprostatik kemik kaybı, Paget hastalığı gibi kemik hastalıklarının tedavisinde ve/veya önlenmesinde kullanılmaktadır.
TR2011/10524A 2011-01-06 2011-10-24 Kemik hastalıklarının tedavisinde kullanılmak üzere suda çözünebilir yeni formülasyonlar. TR201110524A2 (tr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
TR2011/10524A TR201110524A2 (tr) 2011-01-06 2011-10-24 Kemik hastalıklarının tedavisinde kullanılmak üzere suda çözünebilir yeni formülasyonlar.
PCT/TR2012/000006 WO2012093975A1 (en) 2011-01-06 2012-01-06 Water soluble formulations comprising ibandronate sodium with a water content less than 11 % by weight

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2011/00151A TR201100151A2 (tr) 2011-01-06 2011-01-06 İbandronate formülasyonu.
TR2011/10524A TR201110524A2 (tr) 2011-01-06 2011-10-24 Kemik hastalıklarının tedavisinde kullanılmak üzere suda çözünebilir yeni formülasyonlar.

Publications (1)

Publication Number Publication Date
TR201110524A2 true TR201110524A2 (tr) 2012-07-23

Family

ID=45688958

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2011/10524A TR201110524A2 (tr) 2011-01-06 2011-10-24 Kemik hastalıklarının tedavisinde kullanılmak üzere suda çözünebilir yeni formülasyonlar.

Country Status (2)

Country Link
TR (1) TR201110524A2 (tr)
WO (1) WO2012093975A1 (tr)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602004032577D1 (de) * 2003-12-23 2011-06-16 Alchymars S P A Amorphe Form das Natriumsalzes der Ibandronsäure
MX2007000087A (es) * 2004-06-23 2007-11-06 Teva Pharma Acido ibandronico solido y cristalino.
WO2007074475A2 (en) * 2005-12-27 2007-07-05 Natco Pharma Limited Novel polymorphic forms of ibandronate
AU2008242788A1 (en) * 2007-04-19 2008-10-30 Dr. Reddy's Laboratories Ltd. Ibandronate sodium polymorphs
US20090118239A1 (en) * 2007-11-05 2009-05-07 Teva Pharmaceutical Industries Ltd. Amorphous and crystalline forms of ibandronate disodium

Also Published As

Publication number Publication date
WO2012093975A1 (en) 2012-07-12

Similar Documents

Publication Publication Date Title
NZ702637A (en) Treatment of amd using aav sflt-1
MX2022001086A (es) Anticuerpos e inmunoconjugados del receptor 1 de folato y usos de los mismos.
IN2015DN00017A (tr)
MX358716B (es) Composiciones estables para el cuidado bucal que comprenden un aminoácido básico , una sal de estroncio y una fuente de ion fluoruro y usos de las mismas.
MX343687B (es) Compuestos sulfonamida tricíclica y métodos para su fabricación y uso.
MX344238B (es) Compuestos de tetrazol y métodos para preparar y usar los mismos.
MX2012003388A (es) Acidos sulfoperoxicarboxilicos, su preparacion y metodos de uso como agentes blanqueadores y antimicrobianos.
MX2013000522A (es) Formulaciones de rifaximina y usos de las mismas.
WO2012006421A3 (en) Diagnosis and treatment of breast cancer
MX2013001677A (es) Formulaciones estables de linaclotida.
EA201390826A1 (ru) ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA
MY188227A (en) Settable compositions comprising wollastonite and pumice and methods of use
WO2016100803A3 (en) Methods of treating tissue calcification
PH12014502512A1 (en) Topical pharmaceutical compositions comprising terbinafine and urea
NZ706983A (en) Treating soluble coffee
MX357166B (es) Anticuerpos que se unen a notum pectinacetilesterasa.
PH12019500690A1 (en) Oral care composition
GB201110777D0 (en) Methods and uses
IN2014DN05980A (tr)
PH12016500058A1 (en) Remineralising oral care products
EA201692149A1 (ru) Композиции для ухода за полостью рта
TR201110524A2 (tr) Kemik hastalıklarının tedavisinde kullanılmak üzere suda çözünebilir yeni formülasyonlar.
PH12015501251A1 (en) Compositions and methods for treating dental caries
EA201291208A1 (ru) Композиция для ухода за волосами
TR201110525A2 (tr) Kemik hastalıklarının tedavisinde kullanılmak üzere suda çözünebilir farmasötik bileşimler.